Elekta wins CE Mark for Unity high-field MR-linac

Elekta (STO:EKTA B) said today it won CE Mark approval in the European Union for its Elekta Unity magnetic resonance radiation therapy system. The Stockholm-based company touted that its Unity system allows clinicians to deliver radiation doses while simultaneously visualizing the tumor and surrounding tissue through MR imaging. The system also features integrated advanced tools that allow the operator to adapt treatment based on anatomical information. “Unity is a tremendous innovation in patient care, one that enables a scan-plan-treat approach to developing tailored regimens that should yield substantive clinical benefits. I am thrilled that our vision of personalized radiation therapy is becoming a clinical reality,” high-field MR-linac concept inventor Bas Raaymakers of the University Medical Center Utrecht said in a press release. “Receiving CE mark for Unity is a big achievement in revolutionizing the field of radiation therapy and a real watershed moment for treating cancer. The change that MR/RT will bring in cancer therapy is paramount in advancing patient treatment. I’m thankful to the MR-linac Consortium members, Philips and our dedicated employees for helping us reach this important day,” CEO &prez Richard Hausmann said in a prepared statement. In January, Elekta said it inked a collaborative sales deal with IBM‘s (NYSE:IBM) Watson Health through which Elekta will offer IBM’s Watson for Oncology with it...
Source: Mass Device - Category: Medical Devices Authors: Tags: Imaging Oncology Regulatory/Compliance Elekta Source Type: news

Related Links:

CONCLUSION: This review identifies the important roles of F-AuNPs in current cancer researches which are undertaken worldwide. The findings of this review confirm that F-AuNP is a new theranostic agent which has great potentials for simultaneous cancer therapy and diagnosis. PMID: 28799495 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
ConclusionPharmacokinetic modeling of FMISO dynamic PET reveals a more detailed characterization of the tumor microenvironment and assessment of response to chemoradiotherapy in HNC patients than a single static image does. In a clinical trial where absence of hypoxia in primary tumor and lymph nodes would lead to de-escalation of therapy, the observed disagreement between visual analysis and pharmacokinetic modeling results would have affected patient management in
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Abstract PURPOSE: At present, a one-size-fits-all approach is typically used for cancer therapy in patients. This is mainly because there is no current imaging-based clinical standard for the early assessment and monitoring of cancer treatment response. Here, the authors have developed, for the first time, a complete computer-aided-prognosis (CAP) system based on multiparametric quantitative ultrasound (QUS) spectroscopy methods in association with texture descriptors and advanced machine learning techniques. This system was used to noninvasively categorize and predict cell death levels in fibrosarcoma mouse tumor...
Source: Health Physics - Category: Physics Authors: Tags: Med Phys Source Type: research
WebMD wasn't a research option when Ivy Brown was diagnosed with Hodgkin's lymphoma in 1974, so her mother looked up her 12-year-old daughter's condition the old-fashioned way, in a hardcover medical volume. "It just said 'fatal,'" Brown explained. Having moved the family to London a month earlier, Brown's parents were still trying to liaise with her pediatrician in the U.S. "My father told me recently that he was sleeping with the phone on his stomach because of the time change," she said. "They were as scared as you can be when you have a child who you think you might lose," Brown explained....
Source: Science - The Huffington Post - Category: Science Source Type: news
We examined the engraftment and differentiation of alkaline phosphatase-positive NSCs expanded from the postnatal subventricular zone (SVZ), 3 months after grafting into the intact young or aged rat hippocampus. Graft-derived cells engrafted robustly into both young and aged hippocampi. Although most graft-derived cells pervasively migrated into different hippocampal layers, the graft cores endured and contained graft-derived neurons. The results demonstrate that advanced age of the host at the time of grafting has no major adverse effects on engraftment, migration, and differentiation of grafted subventricular zone...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS: Serial parametric response mapping of ADC, performed at multiple time points of therapy, may distinguish pseudoprogression from true progression in patients with diffuse intrinsic pontine gliomas treated with peptide-based vaccination.
Source: American Journal of Neuroradiology - Category: Radiology Authors: Tags: PEDIATRICS Source Type: research
The trend in cancer therapy is toward individualized treatments based on patient-specific biology. However, the application of imaging procedures in the radiotherapeutic management of cancers remains nonpersonalized: a “one-protocol-fits-all” practice is often applied in the clinic worldwide. Essentially, the imaging protocols provided by manufacturers are uniformly applied without considering individual differences of patients being scanned. As such, children and petite adults may be overexposed from the default site-specific protocols (eg high-quality head or pelvis protocols) owing to reduced tissue attenuation.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Brief Reports and Opinion Source Type: research
Conclusion: there is no increased risk of doing the lymph node dissection early on.   Dr. Eggener-CON   Basics Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients.  A Mayo study revealed no data showing therapeutic benefit in high risk patients.  For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit. Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nod...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Medical Devices | PET Scan | Radiation Therapy